Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.03.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von James D Douketis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, St. Joseph's Healthcare Hamilton, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, …. Hauptthemen laut MEDLINE: Perioperative Care, Atrial Fibrillation, Anticoagulants, Factor Xa Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Canadian Institutes of Health Research.
Abstract (Originalsprache)
BACKGROUND: There is uncertainty about the perioperative management of patients who are receiving a direct oral anticoagulant (DOAC) and require elective high-bleed-risk surgery, including those who are undergoing a neuraxial or deep peripheral nerve block procedure. OBJECTIVES: The objectives of this pilot trial were to provide preliminary data as to pre-operative residual DOAC levels with different management strategies andro assess the feasibility of a larger trial. METHODS: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot trial was a proof-of-concept, open-label, randomized controlled trial that assessed the feasibility of comparing perioperative DOAC management using an American Society of Regional Anesthesia (ASRA)-based or PAUSE-based approach in patients with atrial fibrillation who needed an elective high-bleed-risk surgery/procedure and/or any neuraxial anesthesia/procedure. RESULTS: There were 159 patients enrolled (86 on apixaban, 12 on dabigatran, and 61 on rivaroxaban), of whom 141 had preoperative DOAC-level testing done. The median (IQR) residual DOAC level was 19 (19-24) ng/mL in the ASRA group and 20 (19-24) ng/mL in the PAUSE group (standardized difference = -0.02). The percentage of patients in the ASRA and PAUSE groups with preoperative residual DOAC levels 50 ng/mL was 2.9% and 2.8%, respectively. CONCLUSION: In this pilot trial, we found that recruitment of DOAC-treated patients who needed an elective high-bleed-risk surgery or neuraxial procedure was feasible and that preoperative residual DOAC levels appeared similar according to ASRA-based and PAUSE-based management approaches, providing the foundation for a larger trial comparing ASRA- and PAUSE-based perioperative DOAC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, St. Joseph's Healthcare Hamilton, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada. Electronic address: jdouket@mcmaster.ca.
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Department of Computing and Software, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
- Hamilton Regional Laboratory Medicine Program, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Anesthesia, Halton Healthcare, Oakville Trafalgar Hospital, Oakville, Ontario, Canada; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
Förderung
- Canadian Institutes of Health Research
Zitieren
APA
Douketis, J. D., Li, N., St John, M., Nixon, J., Moffat, K., Shaw, J., Syed, S., Schulman, S., Gross, P. L., & Spyropoulos, A. C. (2025). Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.03.003
Vancouver
Douketis JD, Li N, St John M, Nixon J, Moffat K, Shaw J, et al. Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.03.003
BibTeX
@article{Douketis2025,
author = {Douketis, James D and Li, Na and St John, Melanie and Nixon, Joanne and Moffat, Karen and Shaw, Joseph and Syed, Summer and Schulman, Sam and Gross, Peter L and Spyropoulos, Alex C},
title = {Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.03.003}
}
EUVIMED